These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 2946356

  • 1. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB, Ahmed SR, Shalet SM, Costello CB, Howell A, Blacklock NJ.
    Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
    [Abstract] [Full Text] [Related]

  • 2. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C, Verhelst J, Chaban M, Denis L.
    Cancer; 1991 Feb 01; 67(3):557-9. PubMed ID: 1824680
    [Abstract] [Full Text] [Related]

  • 3. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ.
    Br Med J (Clin Res Ed); 1985 Jan 19; 290(6463):185-7. PubMed ID: 3155636
    [Abstract] [Full Text] [Related]

  • 4. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
    J Clin Oncol; 1987 Jun 19; 5(6):912-7. PubMed ID: 2953870
    [Abstract] [Full Text] [Related]

  • 5. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun 19; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 6. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Sonoda T.
    Hinyokika Kiyo; 1987 Jan 19; 33(1):141-50. PubMed ID: 2953179
    [Abstract] [Full Text] [Related]

  • 7. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 8. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Nov 01; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 9. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O, Kontturi M.
    Scand J Urol Nephrol Suppl; 1988 Nov 01; 110():109-12. PubMed ID: 2973121
    [Abstract] [Full Text] [Related]

  • 10. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA, Fernandez del Moral P, Plasman JW, Pull HC, van der Meijden AP, Debruyne FM, Hutchinson FG, Furr BJ.
    Eur Urol; 1990 Nov 01; 18 Suppl 3():22-5. PubMed ID: 2151271
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ, Clayton RN, Blackledge G, Bailey LC, Holder G, Lynch SS, Arkell DG, Cottam J, Farrar D, Young CH.
    Cancer Chemother Pharmacol; 1986 Nov 01; 18(1):39-43. PubMed ID: 2944668
    [Abstract] [Full Text] [Related]

  • 12. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
    Petersson F, Hammar M, Mathson K, Hjertberg H, Varenhorst E.
    Scand J Urol Nephrol; 1987 Nov 01; 21(4):267-71. PubMed ID: 2965409
    [Abstract] [Full Text] [Related]

  • 13. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR, Grant JB, Shalet SM, Howell A, Costello CB, Weatherson T, Blacklock NJ.
    Br J Urol; 1986 Oct 01; 58(5):534-8. PubMed ID: 2946355
    [Abstract] [Full Text] [Related]

  • 14. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L, Keuppens F, Mahler C, Debruyne FM, Weil EH, Lunglmayr G, Newling D, Robinson MR, Richards B, Smith PH.
    Prog Clin Biol Res; 1987 Oct 01; 243A():221-7. PubMed ID: 2958852
    [No Abstract] [Full Text] [Related]

  • 15. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C, Denis L.
    Am J Clin Oncol; 1988 Oct 01; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [Abstract] [Full Text] [Related]

  • 16. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K.
    J Endocrinol; 1984 Nov 01; 103(2):R1-4. PubMed ID: 6238116
    [Abstract] [Full Text] [Related]

  • 17. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P.
    J Urol; 1988 Oct 01; 140(4):775-7. PubMed ID: 2971119
    [Abstract] [Full Text] [Related]

  • 18. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA, del Moral PF, Plasman JW, Kums JJ, Delaere KP, Debruyne FM, Hutchinson FJ, Furr BJ.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):933-6. PubMed ID: 2149507
    [Abstract] [Full Text] [Related]

  • 19. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP, Greco J, Huben R.
    Urology; 1987 Nov 20; 30(5):482-3. PubMed ID: 2960064
    [Abstract] [Full Text] [Related]

  • 20. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y.
    Am J Clin Oncol; 1988 Nov 20; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.